GSK plcGSKNYSE
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank86
3Y CAGR+16.4%
5Y CAGR+24.5%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+16.4%/yr
Annual compound
5Y CAGR
+24.5%/yr
Recent deceleration
Percentile
P86
Within normal range
vs 5Y Ago
3x
Strong expansion
Streak
1 yr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| 2025 | 14.72% |
| 2024 | 2.86% |
| 2023 | 13.39% |
| 2022 | 9.34% |
| 2021 | 4.72% |
| 2020 | 4.93% |
| 2019 | 17.34% |
| 2018 | -13.03% |
| 2017 | 23.37% |
| 2016 | 1.91% |